Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avacincaptad pegol + anti-vegf
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Spiegelmers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapy Plasmids → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Protein Replacement mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Natural RNA Aptamers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Unmodified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Long Non-coding RNA (lncRNA) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Based Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic (intravitreal)
01
Overview
This is a **combination of avacincaptad pegol and an anti-VEGF agent**. Avacincaptad pegol is a pegylated RNA aptamer that selectively binds and inhibits complement factor C5 in the complement cascade, thus blocking the cleavage of C5 into C5a and C5b and reducing inflammation and membrane attack complex (MAC) formation. It is approved as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)[1][2][3][4]. Anti-VEGF drugs are a class of biologics or small molecule drugs targeting vascular endothelial growth factor (VEGF), suppressing abnormal neovascularization and vascular permeability, and are standard care in neovascular (wet) AMD and other chorioretinal vascular diseases[5][6]. The rationale for combining avacincaptad pegol with an anti-VEGF agent in trials or practice is to address both the inflammatory pathway involved in GA and the angiogenic pathway implicated in neovascular AMD. No fixed-dose combination pharmaceutical of avacincaptad pegol with an anti-VEGF agent is currently marketed, but combination therapy (sequential or concurrent use of both drugs) is used in research settings for cases of conversion from dry to wet AMD or for coexisting pathologies.
02
Targets
Beyond the preview
Go deeper on avacincaptad pegol + anti-vegf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avacincaptad pegol + anti-vegf.